← Open Payments lookup

NPI 1790722049: Open Payments

NPI 1790722049. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$425 in 19 payments from 9 companies in 2025. Trend: 2023 $1,101 · 2024 $1,540 · 2025 $425

Food & beverage: $425
CompanyPaymentsAmount
Lilly USA, LLC4$113
Novo Nordisk Inc3$79
ABBVIE INC.2$47
Amgen Inc.2$42
Esperion Therapeutics, Inc.2$39
Abbott Laboratories2$38
Salix Pharmaceuticals, a division of Bausch Health US, LLC2$38
Boehringer Ingelheim Pharmaceuticals, Inc.1$19
Phathom Pharmaceuticals, Inc.1$9

Products named: JARDIANCE, MOUNJARO, OTEZLA, NEXLETOL, FREESTYLE LIBRE 3, XIFAXAN, Ozempic, VRAYLAR.